CAPTRUST Financial Advisors
PHIO icon

CAPTRUST Financial Advisors’s Phio Pharmaceuticals PHIO Stock Holding History

CAPTRUST Financial Advisors’s Portfolio PHIO Stock Details PHIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.3K Hold
10,000
– – ﹤0.01% 3236
2026
Q1 		$12.2K Hold
10,000
– – ﹤0.01% 2991
2025
Q4 		$10.5K Buy
+10,000
New +$16K ﹤0.01% 2729

Other funds holding PHIO

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $110B AUM 26.29% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

CAPTRUST Financial Advisors's PHIO Position: Q2 2026 in Review

CAPTRUST Financial Advisors held its Phio Pharmaceuticals (PHIO) position steady in Q2 2026 at 10,000 shares worth $10.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3236.

CAPTRUST Financial Advisors first reported a position in PHIO in Q4 2025 and has held it in 3 quarters since. The position peaked at $12.2K in Q1 2026. 24 funds tracked by Wall St. Rank hold PHIO as of Q2 2026.

  • CAPTRUST Financial Advisors held 10,000 shares of Phio Pharmaceuticals worth $10.3K as of Q2 2026.
  • CAPTRUST Financial Advisors left its Phio Pharmaceuticals share count unchanged in Q2 2026.
  • Phio Pharmaceuticals made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #3236 holding.
  • CAPTRUST Financial Advisors first reported a position in Phio Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • CAPTRUST Financial Advisors's Phio Pharmaceuticals position peaked at $12.2K in Q1 2026.
  • 24 funds tracked by Wall St. Rank held Phio Pharmaceuticals as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.